Antiproliferative Modulation and Pro-Apoptotic Effect of BR2 Tumor-Penetrating Peptide Formulation 2-Aminoethyl Dihydrogen Phosphate in Triple-Negative Breast Cancer.
Laertty Garcia de Sousa Cabral, Cyntia Silva Oliveira, Katielle Albuquerque Freire, Monique Gonçalves Alves, Vani Xavier Oliveira, Jean-Luc Poyet, Durvanei Augusto Maria · Cancers · 2023
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
In a laboratory model, hUVEC cells showed a reduction in the ΔΨm for treatments with peptide BR2, and the effect of the association 2-AEH 2 P+BR2 was substantially lower than that observed in cancer cells, with percentage values of 11.2 ± 3.3% and 13.6 ± 1.3%, respectively ( Figure 4 a,b). The authors concluded that the combination of the BR2 peptide with 2-AEH2P+BR2 may represent a promising therapeutic strategy in TNBC with potential use in clinical settings. These findings from a laboratory model add evidence about molecular hydrogen's biological effects in the model studied.
What the Findings Mean
H2HUBB reviewed how molecular hydrogen was evaluated in this publication and summarizes the source-grounded findings below. HUVEC cells showed a reduction in the ΔΨm for treatments with peptide BR2, and the effect of the association 2-AEH 2 P+BR2 was substantially lower than that observed in cancer cells, with percentage values of 11.2 ± 3.3% and 13.6 ± 1.3%, respectively ( Figure 4 a,b).
What the Researchers Studied
The study used a in vitro cell-culture laboratory experiment. The comparison condition was control condition or baseline measurements.
What Effects Did Molecular Hydrogen Have?
The aim of the present study was to evaluate the potential therapeutic interest of the association of the tumor-penetrating BR2 peptide with monophosphoester 2-aminoethyl dihydrogen phosphate (2-AEH2P), a monophosphoester involved in cell membrane turnover, in TNBC. HUVEC cells showed a reduction in the ΔΨm for treatments with peptide BR2, and the effect of the association 2-AEH 2 P+BR2 was substantially lower than that observed in cancer cells, with percentage values of 11.2 ± 3.3% and 13.6 ± 1.3%, respectively ( Figure 4 a,b). The authors concluded that the combination of the BR2 peptide with 2-AEH2P+BR2 may represent a promising therapeutic strategy in TNBC with potential use in clinical settings.
Why These Findings Matter
This publication adds useful evidence about where molecular hydrogen did and did not change the measured outcomes, helping define the larger therapeutic evidence base.
How Strong Is This Evidence?
This is laboratory evidence from a in vitro cell-culture laboratory experiment. It is most informative for the biological mechanisms, cellular responses, or biochemical outcomes directly measured.
Technical Study Details
H2HUBB classifies this publication as laboratory study with laboratory or cellular evidence. The study used a in vitro cell-culture laboratory experiment.
Limitations and Safety
No separate limitations or safety findings were identified in the current-study source text available to H2HUBB.
Original Study and H2HUBB Research Context
H2HUBB presents this source-grounded research record as one contribution to the broader molecular-hydrogen evidence base.